Men's Health

Presentation at What Ails Males
Oct. 2006

Healthy Aging – For Men

From an Infectious Diseases Standpoint - by Dr. Donald Skllman

Four Eternal Truths:

Prevention of Infections:

Vaccines:

Influenza Vaccine:

The Advisory Committee on Immunization Practices (ACIP) updated their guidelines for antiviral treatment and vaccination for influenza for the 2006 season:

Annual influenza vaccination is recommended for:

There are different types of vaccines:

The live attenuated influenza vaccine is recommended for:

 The live attenuated influenza vaccine is contraindicated in:

Inactivated influenza vaccine is recommended for:

The inactivated influenza vaccine is contraindicated in those with anaphylactic sensitivity to eggs and acute febrile illness.

Updates to 2005 ACIP recommendations:

Influenza Treatment and Prophylaxis

Treatment should follow an accurate diagnosis, and the common cold should not be treated with anti-influenza medications.

Clinical Signs of Influenza vs. the Common Cold

Influenza Common Cold
Onset Abrupt Gradual
Cough Dry, nonproductive, may be severe hacking, +/- productive
Fever Virtually always, >101o F often Practically never
Myalgias Common, often severe Mild or nonexistent
Fatigue Severe, near exhaustion Mild
Nasal Discharge Clear, modest amounts Clear or green/yellow, possibly lots
Sore Throat Sometimes Common
Headache Prominent Rare
Sneezing Sometimes Usually
Stuffy Nose Sometimes Usually

If antiviral treatment of influenza is indicated, oseltamivir or zanamivir can be prescribed. They demonstrate activity against both influenza A and B viruses.

Neuraminidase Inhibitors

Influenza types A and B are RNA viruses with two glycoproteins, hemagglutinin (H) and neuraminidase (N), projecting from the viral surface. The influenza neuraminidase cleaves sialic acid from cellular and viral glycoconjugates, preventing viral aggregation and allowing the release of progeny virus from an infected cell.

Zanamivir  (RelenzaTM)

Zanamivir (Relenza) is an inhaled drug, which requires careful patient education for proper use and has been reported to cause bronchospasm in people with asthma.

Prophylaxis studies show it to be 67 - 82% effective in preventing laboratory evidence of disease and 84 - 95% effective in preventing febrile illness. In treatment of influenza studies, zanamivir reduced the time to alleviation of major symptoms by 1 – 1.5 days (4 days vs. 5 days) compared with placebo. Those who initiate therapy sooner (no later than 30 hours after symptom onset) and those with more pronounced illness may exhibit greater benefit (e.g., a 3-day decrease in symptom duration). High-risk patients receiving zanamivir had significantly fewer complications than those receiving placebo and needed fewer courses of antibiotic medications.

Zanamivir is well tolerated. The most common adverse events are related to the respiratory tract (7% to 11%) or gastrointestinal tract (5% to 9%) and were similar for zanamivir and placebo. High-risk patients receiving zanamivir experienced fewer adverse events (such as asthma and bronchitis) than those receiving placebo. Because of the risk for serious adverse respiratory events and because efficacy has not been demonstrated in patients with underlying airway disease, zanamivir is not recommended for treatment of this population.

      For prophylaxis: 10 mg once a day with the Diskhaler device

      For treatment: 10 mg twice a day for five days with the Diskhaler device

Oseltamivir (TamifluTM)

      An oral inhibitor of influenza A and B neuraminidase. It is effective in the long-term prophylaxis of natural influenza infection, with a protective efficacy of 74 – 84%. Treatment trials showed that it reduces the duration of illness by 1.3 days and the duration of cough is reduced by 24 hours.

      The oral drug is well tolerated. The most common adverse event is gastrointestinal symptoms that are mild and transient. Taking the drug with food prevents these side effects and improves bioavailability. Some subjects in the early trials with this drug developed antibodies against influenza, indicating that they had a subclinical infection but still gained protective immunity.

      For prophylaxis: 75 mg once a day

      For treatment: 75 mg twice a day for five days

Viral resistance to adamantane drugs (Amantadine and Rimantadine) can emerge rapidly during treatment because a single point mutation can result in cross-resistance to both amantadine and rimantadine.  During treatment with either of these agents, drug-resistant viruses can emerge in approximately one third of patients.  In contrast, development of viral resistance to zanamivir and oseltamivir during treatment has been identified but does not appear to be frequent.

Diagnostic tests available for influenza include viral culture, serology, rapid antigen testing, polymerase chain reaction, and immunofluorescence assays.  The sensitivity and specificity of these tests may vary based on the laboratory that performs the test, the type of test used, the type of specimen tested, and the timing of specimen collection.  Nasopharyngeal specimens are typically more effective than throat swab specimens for viral isolation or rapid detection.  As with other diagnostic test, the findings should be evaluated in the context of other available clinical and epidemiologic information.

Prevention of Upper Respiratory Infections  (Colds)

Persons with URI symptoms and people in contact with them should wash their hands frequently to reduce common cold transmission.

Echinacea and vitamin supplements have not been proven as a means of prevention in most patients.

Prophylactic vitamin C is not recommended for the general community, but can be considered for marathon runners, skiers, and soldiers exposed to significant cold or physical stress.

Pneumococcal Vaccine

Pneumococcal 23-valent polysaccharide vaccine is recommended for all adults 65 years of age or older who have not previously received the vaccine, or who received the vaccine more than 5 years earlier.

Pneumococcal and influenza vaccines can be administered concurrently at different sites without increasing side effects.

Hepatitis A

Hepatitis B

Hepatitis B is transmitted by blood, IV drug use, birth, or sex.

Hepatitis B Vaccine is recommended for:

Hepatitis C

Prevention

Don’t use illicit drugs!

Don’t engage in high-risk sexual practices!

Tattoos or body piercings can be risky.

Employment or volunteer work may put you at risk of exposure to infection.

Prophylactic Antibiotics

Healthy Living

Don’t be stupid

GERMS NEVER SLEEP  (but doctors do!)

3.  Fever is our friend

4.  Time stops for no man

In the next 1 minute, 97 people will die:

In the next one minute:

Older people have weaker immune systems

 

About | Services | Find a Doctor | Nursery | Education & Events | Jobs & Volunteers | Foundation | Health & Wellness | Home | Sitemap | Contact |
Patients | Visitors | Physicians | Employees
Copyright 2006 St. Peter's Hospital, all rights reserved -- 2475 Broadway, Helena MT 59601 -- Phone (406) 442-2480